CSF3 and graft versus host disease: We also evaluated the impact of G‐CSF administration on grades II–IV acute GVHD, overall chronic GVHD, neutrophil recovery, relapse, and OS stratified by recipient age, cytogenetic risk, disease status, conditioning regimen, and GVHD prophylaxis for each donor type.